Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290042 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
A Phase 1 study of Ulcerative Colitis and Crohn's Disease, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 8
- Study locations
NCT01290042: Completed Phase 1 study of Ulcerative Colitis and Crohn's Disease, sponsored by Amgen.
NCT01290042 is a Phase 1 study of Ulcerative Colitis and Crohn's Disease that has completed, run by Amgen. The registered enrollment target is 43 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01290042, a Phase 1 study of Ulcerative Colitis and Crohn's Disease, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 8
- Study locations
Study Summary
To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Conditions Studied
Interventions
- DRUG AMG 181
- OTHER Placebo for AMG 181
Study Locations (8)
Connecticut
- Research Site - Bridgeport
- Research Site - Danbury
California
- Research Site - Glendale
Florida
- Research Site - Miami
Pennsylvania
- Research Site - Duncansville
Queensland
- Research Site - Herston
South Australia
- Research Site - Adelaide
Victoria
- Research Site - Prahran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01290042 record still lists
NCT01290042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which AMG 181 is the first listed.
NCT01290042 lists 8 locations in 7 states (Connecticut, California, Florida).
Frequently Asked Questions
What is clinical trial NCT01290042 about?
NCT01290042 is a clinical study titled "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.". To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
What is the current status of trial NCT01290042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2011-02. Estimated completion is 2014-05.
What conditions does trial NCT01290042 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Crohn's Disease.
What interventions are being tested in trial NCT01290042?
The interventions under investigation include: AMG 181 (DRUG), Placebo for AMG 181 (OTHER).
Who is sponsoring clinical trial NCT01290042?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01290042 being conducted?
This trial has 8 study locations across California, Connecticut, Florida, Pennsylvania, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01290042's enrollment target sits among peer trials
43 92nd of 122 higher than 31 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia